The California State Board of Pharmacy recently placed a Sutter Health hospital's pharmacy on a three-year probation, local news outlet Del Norte Triplicate reported Sept. 7. 

A small study of 10 participants found that semaglutide, the generic for Ozempic and Wegovy, could minimize or eliminate the need for Type 1 diabetes patients to take insulin. 

Within two years, Peoria, Ill.-based OSF HealthCare doubled engagement in a program for pharmacists that was originally made for nurses. 

Type 2 diabetes patients who take a GLP-1 such as Ozempic or Wegovy are associated with higher usage of continuous glucose monitors, Dexcom said Sept. 5, according to an Investor's Business Daily report.

Aktiv Pharma Group, a drugmaker based in Broomfield, Colo., plans to shut down two of its three plants and lay off 70 workers, according to multiple news outlets. 

Lupin, a Mumbai, India-based drug company, is collaborating with Mark Cuban Cost Plus Drug Co. to sell its generic chronic obstructive pulmonary disease drug through the mail-order pharmacy. 

Researchers in the U.S. and U.K. are testing Type 2 diabetes drug Ozempic and weight loss therapy Wegovy for their potential in diminishing dementia and addiction, CNBC reported Sept. 7. 

Pharmacists are overworked and understaffed, according to the California Board of Pharmacy, and it may be what is leading them to make up to 5 million errors each year, the Los Angeles Times reported Sept. 5.

Amid a late-summer increase in COVID-19 cases and hospitalizations, the next booster shot targeting XBB.1.5 might be available as early as Sept. 13. 

CMS bookmarked $9 billion for the 2,600 340B hospitals to repay unlawful payment cuts, and nearly half, $4.3 billion, is planned for 100 of those hospitals, according to data from the Community Oncology Alliance.